Serotype-Specific Pneumococcal Status prior to PCV 13 Administration in Children and Adolescents with Inflammatory Bowel Disease


Share / Export Citation / Email / Print / Text size:

Polish Journal of Microbiology

Polish Society of Microbiologists

Subject: Microbiology


ISSN: 1733-1331
eISSN: 2544-4646





Volume / Issue / page

Related articles

VOLUME 65 , ISSUE 1 (March 2016) > List of articles

Serotype-Specific Pneumococcal Status prior to PCV 13 Administration in Children and Adolescents with Inflammatory Bowel Disease

Aleksandra Banaszkiewicz * / Brygida Targońska / Kinga Kowalska-Duplaga / Katarzyna Karolewska-Bochenek / Agnieszka Sieczkowska / Agnieszka Gawrońska / Urszula Grzybowska-Chlebowczyk / Elżbieta Krzesiek / Izabella Łazowska-Przeorek / Maria Kotowska / Edyta Sienkiewicz / Jarosław Walkowiak / Hanna Gregorek / Andrzej Radzikowski / Piotr Albrecht

Keywords : autoimmune disease, Crohn’s disease, PCV, ulcerative colitis, vaccine

Citation Information : Polish Journal of Microbiology. Volume 65, Issue 1, Pages 89-91, DOI:

License : (CC BY-NC-ND 4.0)

Received Date : 16-May-2015 / Accepted: 01-September-2015 / Published Online: 15-March-2016



The aim of this study was to evaluate the serotype-specific pneumococcal status of children and adolescents with inflammatory bowel disease (IBD) who were naïve to pneumococcal vaccination before administering the 13-valent pneumococcal conjugate vaccine (PCV 13). This was an open, prospective study on children and adolescents aged 5–18 years who had IBD and were naïve to pneumococcal vac­cination. A single dose of PCV 13 was administered to each patient. The geometric mean concentrations (GMCs) were measured for all 13 serotypes. A total of 122 subjects completed the study. Prevaccination GMCs ranged from 0.55 μg/ml (serotype 4) to 4.26 μg/ml (sero­type 19A). Prior to the administration of PCV 13, high GMCs were detected in older children and adolescents who had IBD and were naïve to pneumococcal vaccination.

Content not available PDF Share



Bamford A., P. Kelleher, H. Lyall, M. Haston, M. Zancolli, D. Goldblatt and B. Kampmann. 2014. Serological response to 13-valent pneumococcal conjugate vaccine in children and adoles¬cents with perinatally acquired HIV infection. AIDS 28: 2033–2243.


Centers for Disease Control and Prevention (CDC). 2013. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneu-mococcal polysaccharide vaccine among children aged 6–18 years with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb. Mortal. Wkly. Rep. 62: 521–524.


Concepcion N.F. and C.E. Frasch. 2001. Pneumococcal type 22F polysaccharide absorption improves the specificity of a pneumo¬coccal-polysaccharide enzyme-linked immunosorbent assay. Clin. Diagn. Lab. Immunol. 8: 266–272.


Frenck R.Jr., A. Thompson, S. Senders, L. Harris-Ford, M. Sper¬ling, S. Patterson, C. Devlin, K.U. Jansen, W.C. Gruber, E.A. Eminiand others. 2014. 13-Valent pneumococcal conjugate vaccine in older children and adolescents either previously immunized with or naïve to 7-valent pneumococcal conjugate vaccine. Pediatr. Infect. Dis. J. 33: 183–189.


Levine A., S. Koletzko, D. Turner, J.C. Escher, S. Cucchiara, L. de Ridder, K.L. Kolho, G. Veres, R.K. Russell, A. Paerregaard and others. 2014. ESPGHAN revised porto criteria for the diagnosis of inflammatory bowel disease in children and adolescents. J. Pediatr. Gastroenterol. Nutr. 58: 795–806.


Rubin L.G., M.J. Levin, P. Ljungman, E.G. Davies, R. Avery, M. Tomblyn, A. Bousvaros, S. Dhanireddy, L. Sung, H. Keyserling and others. 2014. Infectious diseases society of America. 2013 IDSA clinical practice guideline for vaccination of the immunocompro¬mised host. Clin. Infect. Dis. 58:309–318.


Skoczyńska A., A. Kuch, E. Sadowy, I. Waśko, M. Markowska, P. Ronkiewicz, B. Matynia, A. Bojarska, K. Wasiak, A. Gołębiewskaand others. 2015. Participants of a laboratory-based surveillance of community acquired invasive bacterial infections (BINet). Recent trends in epidemiology of invasive pneumococcal disease in Poland. Eur. J. Clin. Microbiol. Infect. Dis. 34: 779–787.


World Health Organisation (WHO). 2005. Pneumococcal conjugatevaccines. Recommendations for the production and control of pneu-mococcal conjugate vaccines. WHO Tech. Rep. Ser. 927 (Annex 2): 64–98.


Wernette C.M., C.E. Frasch, D. Madore, G. Carlone, D. Goldblatt, B. Plikaytis, W. Benjamin, S.A. Quataert, S. Hildreth, D.J. Sik-kema and others. 2003. Enzyme-linked immunosorbent assay for quantitation of human antibodies to pneumococcal polysaccharides. Clin. Diagn. Lab. Immunol. 10: 514–519.


Wysocki J., J. Brzostek, H. Szymański,B. Tetiurka, E. Toporowska-Kowalska, K. Wasowska-Królikowska, D.A. Sarkozy, P.C. Giar¬dina, W.C. Gruber and others. 2015. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine administered to older infants and children naïve to pneumococcal vaccination. Vaccine 33: 1719–1725.